Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4905 |
Name | pancreatic carcinoma |
Definition | A pancreas cancer that derives_from epithelial cells located_in the exocrine pancreas. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V487_P492delinsA | LXH 254 | pancreatic carcinoma | sensitive | detail... |
BRAF V487_P492delinsA | Trametinib | pancreatic carcinoma | sensitive | detail... |
BRAF V487_P492delinsA | Encorafenib | pancreatic carcinoma | decreased response | detail... |
BRAF V487_P492delinsA | Sorafenib | pancreatic carcinoma | sensitive | detail... |
BRAF V487_P492delinsA | Ulixertinib | pancreatic carcinoma | predicted - sensitive | detail... |
BRAF V487_P492delinsA | LXH 254 + Trametinib | pancreatic carcinoma | predicted - sensitive | detail... |
BRAF V487_P492delinsA | Sorafenib + Trametinib | pancreatic carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01537107 | Phase I | Sirolimus + Vismodegib | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01663272 | Phase I | Cabozantinib + Gemcitabine | A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01954732 | Phase I | Metformin | Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery | Withdrawn | 0 | |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | FIN | ESP | DEU | CHE | BEL | 3 |
NCT02847000 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | Completed | USA | 0 |
NCT02930902 | Phase I | Paricalcitol + Pembrolizumab Gemcitabine + Nab-paclitaxel + Paricalcitol + Pembrolizumab | Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer | Completed | USA | 0 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03825289 | Phase I | Hydroxychloroquine + Trametinib | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD) | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT04386057 | Phase II | Hydroxychloroquine + LY3214996 LY3214996 | LY3214996 +/- HCQ in Pancreatic Cancer | Completed | USA | 0 |
NCT04431258 | Phase Ib/II | ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) | Completed | USA | ISR | FRA | ESP | 0 |
NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |
NCT05042128 | Phase II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) | Active, not recruiting | NZL | AUS | 0 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05721846 | Phase I | Ipilimumab + Nivolumab + TGF-beta-15 peptide vaccine | Nivolumab With Ipilimumab Combined With TGFb-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC) | Recruiting | DNK | 0 |
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06445062 | Phase Ib/II | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 Gemcitabine + Nab-paclitaxel + RMC-6236 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RMC-6236 Cetuximab + RMC-6236 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |